


PRODUCT INFORMATION



TAK-960

Item No. 17701

CAS Registry No.: 1137868-52-0
Formal Name: 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methyl-4-piperidinyl)-benzamide
MF: C₂₇H₃₄F₃N₇O₃
FW: 561.6
Purity: ≥95%
UV/Vis.: λ_{max}: 280, 330 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TAK-960 is supplied as a crystalline solid. A stock solution may be made by dissolving the TAK-960 in the solvent of choice, which should be purged with an inert gas. TAK-960 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of TAK-960 in these solvents is approximately 12, 20, and 25 mg/ml, respectively.

TAK-960 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, TAK-960 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. TAK-960 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Polo-like kinases (Plks) are serine/threonine kinases with key roles in cell cycling. TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC₅₀ values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.^{1,2} It exhibits greater than 20-fold selectivity for Plk1 over FAK, MLCK, and the tyrosine protein kinase Fes, and has minimal activity against a panel of 282 other kinases.^{1,2} It inhibits the proliferation of various cancer cell lines, including MDR1-expressing tumors, and also prevents tumor growth in several human cancer cell xenograft models, including a disseminated model of AML- and MDR1-expressing hematological tumors.^{1,2}

References

1. Hikichi, Y., Honda, K., Hikami, K., *et al.* TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. *Mol. Cancer Ther.* **11**(3), 700-709 (2012).
2. Nie, Z., Feher, V., Natala, S., *et al.* Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1). *Bioorg. Med. Chem. Lett.* **23**(12), 3662-3666 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM